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Purpose: We have previously shown that non-psychotropic cannabidiol (CBD) protects retinal neurons in diabetic rats
by inhibiting reactive oxygen species and blocking tyrosine nitration. Tyrosine nitration may inhibit glutamine synthetase
(GS), causing glutamate accumulation and leading to further neuronal cell death. We propose to test the hypothesis that
diabetes-induced glutamate accumulation in the retina is associated with tyrosine nitration of GS and that CBD treatment
inhibits this process.
Methods: Sprague Dawley rats were made diabetic by streptozotocin injection and received either vehicle or CBD (10 mg/
kg/2 days). After eight weeks, retinal cell death, Müller cell activation, GS tyrosine nitration, and GS activity were
determined.
Results: Diabetes causes significant increases in retinal oxidative and nitrative stress compared with controls. These
effects were associated with Müller cell activation and dysfunction as well as with impaired GS activity and tyrosine
nitration of GS. Cannabidiol treatment reversed these effects. Retinal neuronal death was indicated by numerous terminal
deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL)-labeled cells in diabetic rats compared with untreated
controls or CBD-treated rats.
Conclusions: These results suggest that diabetes-induced tyrosine nitration impairs GS activity and that CBD preserves
GS activity and retinal neurons by blocking tyrosine nitration.
Diabetic  retinopathy  (DR)  is  the  leading  cause  of
blindness in working-age adults, affecting nearly 21 million
people  in  the  United  States  alone  (American  Diabetes
Association). The early clinical features of DR in patients with
diabetes  as  well  as  observations  in  experimental  diabetes
include  vascular  permeability  and  vitreoretinal
neovascularization secondary to vascular dysfunction as well
as retinal glial dysfunction and neuronal cell loss (reviewed
in [1,2]). The biochemical mechanisms involved in diabetic
retinopathy are complex and include the activation of several
cellular pathways (reviewed in [3]). Previously, we and others
have shown that an increase in peroxynitrite, as indicated by
tyrosine  nitration,  correlates  with  accelerated  retinal
endothelial cell death, breakdown of the blood-retinal barrier
(BRB), and accelerated neuronal cell death in experimental
models of diabetes, inflammation, and neurotoxicity [4-15].
These  studies  suggest  peroxynitrite  plays  a  key  role  in
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mediating different aspects of DR. However, the causal role
of diabetes-induced tyrosine nitration in mediating Müller
glial cell injury and dysfunction has not been elucidated.
In response to hyperglycemia-induced oxidative stress,
both microglial and macroglial cells are activated, and the
function of macroglia in transporting glutamate by glutamate
transporters  and  in  metabolizing  glutamate  by  glutamine
synthetase (GS) may be impaired [16-18]. This may lead to
glutamate accumulation, such as that reported in the vitreous
humor of diabetic patients [19] and in the retina of diabetic
animals  [16,20].  Recent  studies  demonstrated  that  GS  is
susceptible  to  tyrosine  nitration,  which  subsequently  can
impair  the  enzyme  activity  [21,22].  Together,  these
observations  prompted  us  to  study  the  role  of  diabetes-
induced tyrosine nitration in mediating glial injury and GS
dysfunction.
Cannabinoids  are  known  to  possess  therapeutic
properties, including anti-oxidant, anti-inflammatory, and N-
methyl-D-aspartic  acid  (NMDA)  receptor-activation
blocking  activity  [23-25].  Non-psychotropic  cannabidiol
(CBD) has been shown to prevent neuronal damage to the
central nervous system in gerbils caused by cerebral ischemia
[26]. We recently demonstrated the neuroprotective effect of
CBD  via  antioxidant  and  anti-inflammatory  action  in  rat
models  of  NMDA-induced  retinal  neurotoxicity  and
lipopolysaccharide (LPS)-induced neurotoxicity [9,15,27] as
well as the anti-inflammatory and BRB-preserving effects in
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1487diabetic  rats  [12].  However,  the  mechanism  of  the
neuroprotective effect of CBD via preserving glial function in
diabetic  retina  has  not  been  studied.  The  present  study
evaluates the ability of CBD to reduce oxidative and nitrative
stress, preserve GS function, and prevent neuronal cell death
in experimental diabetes.
METHODS
Experimental animals and retina isolation: Eight-week-old
male  Sprague  Dawley  rats  (≥200  g)  were  obtained  from
Charles River (Wilmington, MA) and made diabetic by tail-
vein injection of streptozotocin (STZ; Sigma, St. Louis, MO)
65 mg per kg of bodyweight in 0.1 M citrate-buffered saline,
pH 4.5. All procedures involving animals were performed in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and with Medical College
of  Georgia  (Augusta,  GA)  guidelines.  Diabetes  was
confirmed by detection of glucose in the urine and blood of
injected animals (>250 mg/dl). Three sets of animals were
prepared for a total of 48 rats to study the effects of eight weeks
of induced diabetes. The following groups were prepared:
untreated  controls,  controls  treated  with  CBD,  untreated
diabetics, and diabetics treated with CBD. The CBD-treated
groups received intraperitoneal injections of CBD (10 mg/kg)
every other day. Cannabidiol was obtained from the National
Institute of Drug Abuse (Research Triangle Park, NC), and a
fresh solution in 0.25 ml of 1:1:18 alcohol:cremorphol:Ringer
solution  was  prepared.  Control  groups  received  vehicle
injections at the same time points. Streptozotocin-injected
animals  had  significant  increases  in  blood  glucose  level
(495±35 mg/dl) compared with untreated controls (135±7 mg/
dl). Treatment with CBD did not alter blood glucose levels in
diabetic  animals  (455±37  mg/dl)  or  in  treated  controls
(125±5  mg/dl).  After  eight  weeks  of  diabetes,  eyes  were
enucleated and retinas were dissected for further analyses.
Glutamine synthetase activity: Frozen retinas were thawed
and pulse-sonicated in ice-cold sonication buffer (PBS with
1 mM 2- mercaptoethanol). The ability of an aliquot to convert
14C-glutamate  to  14C-glutamine  was  measured  by  a
modification of a published method [28]. Briefly, 30 µl of
sample were reacted with an equivalent volume of reaction
buffer  (100  mM  imidazole  HCl,  pH  7.2,  30  mM  MgCl2,
20 mM ATP, 8 mM NH4Cl, 1 mM 2-mercaptoethanol, and
14 mM 14C-glutamate; Specific Activity, 5×105 CPM/ml) for
20 min at 37 °C. The reaction was stopped by adding 600 µl
of 2% perchloric acid (PCA). In the control reactions, PCA
was  added  at  the  beginning  of  the  incubation  period.
Glutamine  was  then  separated  from  glutamate  by  anion
exchange chromatography (AG 1-X8 Resin Acetate form;
Bio-Rad, Hercules, CA) and quantified by liquid scintillation
counting  [29].  Numbers  were  normalized  to  proteins
measured by DC Protein Assay (Bio-Rad).
Immunoprecipitation and western blot analysis of glutamine
synthetase:  Individual  rat  retinas  were  dissected  and
homogenized in a Mini-Bead beater with treated Ottawa sand
in  250  μl  of  modified  RIPA  buffer  supplemented  with
inhibitors  for  proteases  and  phosphatases  as  described
previously [12]. Retinal protein extract was determined by
DC  Protein  Assay  (Bio-Rad).  The  supernatants  containing
500 μg of protein were combined with 5 µl of polyclonal anti-
glutamine synthetase Santa Cruz Biotechnology (Santa Cruz,
CA) and 50 µl of protein A/G agarose (Santa Cruz) and mixed
overnight at 4 °C. The immunoadsorbents were recovered by
centrifugation for 5 min at 700× g and washed three times in
modified RIPA buffer and twice in 50 mM Tris (pH 7.5)
containing 0.1% (w/v) sodium dodecyl sulfate and 150 mM
NaCl. The samples were eluted into 60 µl of sodium dodecyl
sulfate loading buffer and subjected to sodium dodecyl sulfate
PAGE. The membranes were incubated with polyclonal anti-
nitrotyrosine  (1:1,000;  Upstate  Biotechnology,  Millipore,
Billerica,  MA)  and  then  with  peroxidase-conjugated  goat
antirabbit (1:5,000) for detection of immunoreactive bands by
ECL  advance  chemiluminescence  (GE  Healthcare,
Piscataway, NJ).
Terminal dUTP nick end-labeling analysis: Terminal dUTP
nick end-labeling (TUNEL) analysis was performed using the
ApopTag  Fluorescein  In  Situ  Apoptosis  Detection  Kit
(Millipore)  following  the  manufacturer’s  directions  as
described previously [9]. Briefly, OCT-frozen eye sections
(10 µm) from each group were fixed using paraformaldehyde
(PFA) and ethanol:acetic acid (2:1). Then, the samples were
incubated  with  Terminal  Deoxynucleotidyl  Transferase
followed  by  incubation  with  anti-digoxigenin  conjugate.
Propidium iodide 1 µg/ml was added as a nuclear counter
stain. On completion of the TUNEL assay, coverslips were
applied  using  VECTASHIELD  Mounting  Medium  for
fluorescence (Vector Laboratories, Burlingame, CA). Each
section  was  systematically  scanned  for  positive  green
fluorescent cells in retinal layers indicating apoptosis. Images
were obtained using an AxioObserver.Z1 Microscope (Carl
Zeiss, Oberkochen, Germany) with 200× magnification. Four
to five animals were used for each group, and the number of
TUNEL positive cells were counted in four fields of the mid-
peripheral retina and calculated as the number per mm2 of
retinal area.
Immunolocalization studies: The distribution of nitrotyrosine,
glial fibrillary acidic protein (GFAP), and caspase-3 in frozen
eye  sections  was  analyzed  using  immunolocalization
techniques as described previously [12]. Retinal sections were
fixed with 4% paraformaldehyde and then reacted with a
polyclonal rabbit anti-nitrotyrosine (Millipore), mouse anti-
GFAP (Cell Signaling Technology, Danvers, MA) antibody,
or  rabbit  caspase-3  antibody  (Cell  Signaling  Technology)
followed  by  Oregon  Green-conjugated  goat  antirabbit  or
antimouse antibody (Molecular Probes, Carlsbad, CA). Data
(10 fields/retina, n=6 in each group) were analyzed using
fluorescence  microscopy  and  UltraVIEW  morphometric
software to quantify the intensity of immunostaining. For
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cells, retina sections were stained with mouse Brn-3 antibody
(Santa  Cruz  Biotechnology)  followed  by  Texas  Red-
conjugated antibody (Molecular Probes).
Dichlorofluorescein assay: Dichlorofluorescein (DCF) is the
oxidation  product  of  the  reagent  2’,7’-dichlorofluorescin
diacetate  (H2DCFDA;  Molecular  Probes,  Eugene,  OR),  a
marker  of  cellular  oxidation  by  hydrogen  peroxide  and
peroxynitrite [12]. Earle’s balanced salt solution containing
H2DCFDA  was  incubated  with  retina  sections,  and  the
fluorescence  of  DCF  was  measured  and  analyzed.  The
average retinal fluorescence intensity (10 fields/retina, n=6 in
each  group)  was  analyzed  using  AxioObserver.Z1
Microscope and Axio-software (Carl Zeiss).
Data  analysis:  The  results  are  expressed  as  mean±SEM.
Differences among experimental groups were evaluated by
performing an ANOVA (ANOVA), and the significance of
differences between groups was assessed by a post-hoc test
(Fisher’s PLSD) when indicated. Significance was defined as
p<0.05.
RESULTS
Cannabidiol reduces diabetes-induced oxidative and nitrative
stress: We have previously shown the neuroprotective effects
of CBD in short-term diabetes via inhibiting oxidative and
nitrative stress [12]. Here, we tested the antioxidant effect of
CBD after eight weeks of diabetes. As shown in Figure 1A,
diabetes-induced neurotoxicity involved significant tyrosine
nitration  within  retinal  layers  with  the  strongest
immunoreactivity  in  the  ganglion  cell  layer.  Quantitative
analysis showed that levels of tyrosine nitration increased
~1.6-fold  in  the  diabetic  retinas  in  comparison  with  the
controls  (Figure  1B).  This  tyrosine  nitration  was  almost
completely  eliminated  by  CBD  (10  mg/kg/2  days).  The
antioxidant effect of CBD was further confirmed by blocking
the fluorescence of DCF, a general marker for both oxidative
and nitrative stress in diabetic retinas (Figure 1C,D). The
treated control rat retinas were not affected by CBD treatment.
Cannabidiol  prevents  diabetes-induced  Müller  glial  cell
injury: Glial activation, as indicated by GFAP, is a common
response to stress conditions. There are two types of glial cells
in  the  retina:  astrocytes  and  Müller  cells.  Therefore,  we
assessed  glial  injury  in  response  to  the  diabetic  insult  by
immunolocalization  of  GFAP.  Astrocytes  were  notably
positively and equally labeled with GFAP in all groups. As
shown  in  Figure  2,  only  retinas  from  the  diabetic  group
demonstrated  an  increase  in  the  intensity  of  GFAP
immunoreactivity  in  the  filaments  of  Müller  cells  that
extended from the nerve fiber layer and inner plexiform layer
into the outer nuclear layer of retina as compared with controls
or the CBD-treated group.
Cannabidiol prevents diabetes-induced glutamine synthetase
nitration  and  restores  its  activity:  Diabetes-induced
peroxynitrite  formation  and  its  subsequent  alteration  of
protein function via tyrosine nitration are well documented
[30].  Recent  studies  have  demonstrated  that  GS  is  a
susceptible target for tyrosine nitration [21]. Therefore, we
evaluated the specific tyrosine nitration levels of GS and the
extent to which its activity can be altered in diabetic rat retinas.
As shown in Figure 3, diabetes caused significant tyrosine
nitration (2.3-fold) of GS that was significantly reduced by
treatment with CBD. We next evaluated the effects of tyrosine
nitration on GS activity. Indeed, diabetes-induced GS tyrosine
nitration was positively correlated with a significant inhibition
(40%) of GS activity (Figure 4), and treatment with CBD
restored this activity in the diabetic animals. These results
suggest a causal role of tyrosine nitration in impairing the
function  of  GS,  which  can  lead  to  the  accumulation  of
glutamate and possibly cause neurotoxicity.
Cannabidiol prevents diabetes-induced neuronal cell death
and  activation  of  caspase-3:  We  next  evaluated  neuronal
death after eight weeks of diabetes. Our results demonstrated
that diabetic rat retina showed significant increases in TUNEL
positive cells (~8-fold) mainly in retinal ganglion cells and
inner retinal layers compared with controls. Treatment with
CBD blocked neuronal cell death in diabetic animals but did
not affect treated controls (Figure 5A,B). Neuronal cell death
in  diabetic  animals  was  further  confirmed  by  prominent
immunostaining of caspase-3, a known marker for apoptosis,
within  the  ganglion  cell  layer  (GCL)  as  indicated  by  the
specific retinal ganglion cell marker Brn-3. The ganglion cell
layer notably includes ~35%–40% displaced amacrine cells
in addition to retinal ganglion cells. Treatment with CBD
blocked neuronal cell death in diabetic animals but did not
affect treated controls (Figure 5C,D).
DISCUSSION
Diabetes-induced retinal oxidative and nitrative stress have
been well documented in patients and animals and have been
positively correlated with neuronal cell death [12,13,31-34].
In response to neuronal injury, glial cells including microglial
and macroglial cells are activated. This might be followed by
neuroinflammation, during which activated microglial cells
release  TNF-alpha  and  migrate  toward  dying  neurons  to
further exacerbate the damage [35]. However, the effects of
diabetes-induced oxidative and nitrative stress on macroglial
activation and how this can affect neuronal function have not
been fully elucidated. Indeed, our results showed a significant
increase  in  oxidative  and  nitrative  stress  as  indicated  by
significant increases in DCF fluorescence and nitrotyrosine as
well as prominent Müller glial cell activation compared with
controls. Exposure of retinal Müller glial cells to high glucose
levels stimulates oxidative stress and peroxynitrite formation
( [36], unpublished data). However, peroxynitrite produced
by glial cells is not toxic by itself but causes activation and
expression of proinflammatory cytokines [37]. Our previous
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1489Figure 1. Cannabidiol (CBD) reduces oxidative and nitrative stress in diabetic retinas. A: Representative images show the distribution of
nitrotyrosine immunolocalization in different retinal layers, the ganglion cell layer (GCL), the inner plexiform layer (IPL), the inner nuclear
layer (INL), and the outer nuclear layer (ONL), and the retinal pigment epithelium (RPE) (magnification, 200×). B: Morphometric analysis
of fluorescence intensity in serial sections of rat eyes shows that diabetic rats had a significant increase in fluorescence compared with controls.
Treatment with CBD (10 mg/kg/2 days) inhibited nitrotyrosine formation in the diabetic rats but not in the normal controls. Data shown are
the mean±SEM of six or seven animals in each group (*p<0.05). C: Representative images show the distribution of dichlorofluorescein (DCF)
fluorescence in different retinal layers, the GCL, the IPL, the INL, and the ONL, and the RPE (magnification, 200×). D: CBD reduces peroxides
in the retinas of diabetic rats as represented by morphometric analysis of DCF fluorescence showing that diabetic rats had a significant increase
in fluorescence compared with controls. Treatment with CBD (10 g/kg/2 days) inhibited reactive oxygen species formation in diabetic rats
but not normal controls. Data shown is the mean±SEM of five or six animals in each group (*p<0.05).
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1490studies have shown that Müller cells are not among the retinal
cell population undergoing apoptosis early in diabetes [13].
Our current study demonstrated that Müller cells are activated
as  evidenced  by  an  enhanced  intensity  of  GFAP
immunoreactivity in the filaments of Müller cells in diabetic
retinas that was blocked by CBD treatment.
Previous studies have documented the adverse effects of
diabetes  on  the  function  of  Müller  cells  in  transporting
glutamate  by  glutamate  transporter  or  in  metabolizing
glutamate  by  GS  [16-18,20].  Although  alterations  in
glutamate  transporter  activity  during  diabetes  remain
controversial, impairment of GS activity has been previously
reported [38-40]. Interestingly, recombinant GS enzyme from
Figure 2. Cannabidiol (CBD) prevents Müller cell activation in diabetic animals. Representative images of glial fibrillary acidic protein (GFAP)
showing abundant immunofluorescence at the end-feet of the Müller cells and the radial processes stained intensely throughout both the inner
and outer retina in the diabetic retinas compared with normal controls. This effect was blocked by treatment with CBD (10 mg/kg/2days, i.p.).
Similar results were obtained from five additional animals per group.
Figure 3. Cannabidiol (CBD) reduces
GS  nitration  in  diabetic  (D)  animals.
Immunoprecipitation  with  anti-
glutamine synthetase (GS) and western
blot  analysis  using  anti-nitrotyrosine
antibody  show  that  diabetes
significantly  increased  the  tyrosine
nitration of GS compared with normal
retinas.  This  effect  was  blocked  by
treatment with CBD (10 mg/kg/2days,
i.p.;  n=4–6  retinas/group,  *p<0.05,
versus control [standard error of mean]).
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1491E. coli, rat liver, or mammalian GS has been reported to be a
susceptible target for tyrosine nitration that might reduce its
activity [21,22,41]. Therefore, we investigated GS nitration
and its impact on GS activity in diabetic rat retinas. Our results
showed a 2.3 fold increase in GS tyrosine nitration that was
associated with a significant reduction (40%) in GS activity
in diabetic retinas compared with controls. Our results lend
further support to previous reports showing that diabetes can
alter  glial  function  and  impair  GS  activity  [38,42,43].
Although the concept of GS nitration and the subsequent
impairment  of  its  activity  has  been  demonstrated  at  the
recombinant protein level, we believe our study provides the
first  experimental  evidence  in  a  diabetic  model.  Further
studies of human samples should provide clinical evidence
and implications for GS nitration.
Tyrosine  nitration  and  the  subsequent  loss  of  protein
function have been documented in response to peroxynitrite
[11,30,44-46]. Furthermore, the impact of GS nitration and its
impairing activity is evidenced by glutamate accumulation, as
reported in the vitreous humor of diabetic patients [19] and in
the  retinas  of  diabetic  animals  [16,17,20].  Glutamate
excitotoxicity occurs via the activation of NMDA receptors
to induce calcium influx and the release of superoxide and
nitric oxide, leading to the formation of peroxynitrite and
neuronal death [47,48]. Diabetes-impaired GS activity should
lead to the accumulation of glutamate and the formation of
peroxynitrite, which in turn can sustain tyrosine nitration and
the  inhibition  of  GS  activity.  This  vicious  cycle  of  glial
dysfunction will result in cell death and the injury of adjacent
retinal neurons. Therefore, we next evaluated neuronal cell
death  in  the  diabetic  animals.  Indeed,  our  results  showed
significant  increases  in  TUNEL-positive  cells  that  were
mainly localized in retinal ganglion cells and inner retinal
layers  in  the  retinas  of  diabetic  animals  compared  with
controls.  Additional  immunolocalization  studies  using
caspase-3, a known apoptotic marker, and Brn-3, the specific
retinal ganglion cell marker, confirmed apoptosis of ganglion
cells in the diabetic animals. As further support, previous
studies  have  demonstrated  retinal  ganglion  cell  loss  in
response to STZ diabetes within the same time frame, eight
weeks  [49],  that  continues  to  happen  later  during  the
progression  of  the  disease  [32].  Retinal  ganglion  cells
represent about 60%–65% of neurons in addition to displaced
amacrine  cells  in  the  ganglion  cell  layer.  These  findings
suggest a loop where diabetes-induced oxidative and nitrative
stress  alter  the  function  of  Müller  cells  by  impairing  GS
activity, leading to glutamate neurotoxicity and sustaining
retinal neuronal death.
Treating  diabetic  animals  with  CBD  blocked  the
increases in oxidative and nitrative stress and significantly
reduced the number of apoptotic cells. Neurons are highly
susceptible to oxidative stress, which can induce apoptosis;
therefore, it is likely that diabetes-induced oxidative stress
leads to neuronal injury. Several reports have described the
neuroprotective effects of CBD via blocking reactive oxygen
species or nitrotyrosine formation in glutamate-induced cell
death  in  neuron  cultures  and  in  an  NMDA-induced
neurotoxicity [9,12,15,25]. Here, we demonstrate a novel role
of  CBD  in  restoring  GS  activity  by  reducing  its  tyrosine
nitration in diabetic animals. This effect was associated with
a significant reduction in Müller glial cell activation, which
confirms the preservation of its morphology and function in
the diabetic animals. Together, our present findings suggest
that CBD represents novel therapeutics in the treatment of
diabetes and stress-mediated retinal damage. Furthermore,
CBD is an attractive medical alternative to smoked marijuana
or plant extract because of its lack of psychoactive effect and
because it is well tolerated in humans when administered
chronically [50,51]. In addition, CBD has been approved for
the treatment of inflammation, pain, and spasticity associated
with  multiple  sclerosis  in  humans  (reviewed  in  [52]).  In
conclusion,  the  data  presented  here  provide  experimental
Figure 4. Cannabidiol (CBD) restores
diabetes-impaired glutamine synthetase
(GS)  activity.  Glutamine  synthetase
activity measured by the ability of the
sample to convert 14C-glutamate to 14C-
glutamine  demonstrated  significant
inhibition of GS activity in diabetic rat
retinas compared with controls. The GS
activity  was  restored  by  treating  the
diabetic animals with CBD (10 mg/kg/
2days,  i.p.;  n=4–5  retinas/group,
*p<0.05, versus control [standard error
of mean]).
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1492Figure 5. Retinal neuroprotective effect of cannabidiol (CBD) in experimental diabetes. A: Representative images show the terminal
deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) labeling of frozen eye sections from the diabetic rats (eight weeks) in different
retinal layers. TUNEL-positive cells (arrows) were distributed mainly in the inner retinal layers. B: Statistical analysis of TUNEL-positive
nuclei in various groups. At least four fields per mid-peripheral retina were counted for each retina from one animal. (n=4–5 retinas/group,
*p<0.05, versus control [standard error of mean]). Treating the diabetic animals with CBD (10 mg/kg/2 days, i.p.) prevented neuronal death.
C: Representative images show the localization of the apoptotic marker caspase-3 in the ganglion cell layer and the inner retinal layer in
diabetic retina sections but not in other groups. D: Enlarged window of retina sections showing colocalization (yellow) of the apoptotic marker
caspase-3 (green) within the retinal ganglion cell layer labeled with Brn-3 (red). The layers shown are the ganglion cell layer (GCL), the inner
plexiform layer (IPL), the inner nuclear layer (INL), and the outer nuclear layer (ONL).
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1493evidence that diabetes-activated retinal glial cells represent a
central player in retinal neurodegeneration.
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